Literature DB >> 15225673

Time response of carboplatin-induced nephrotoxicity in rats.

Kazim Husain1, Craig Whitworth, Leonard P Rybak.   

Abstract

Carboplatin, a second-generation platinum-containing anti-cancer drug, is currently being used against human cancers. High-dose carboplatin chemotherapy can cause renal tubular injury in cancer patients. We have shown a dose-dependent nephrotoxicity of carboplatin in a rat model. However, the time response of carboplatin-induced renal injury has not been explored. This study investigated the time response of carboplatin-induced nephrotoxicity in rat. Male Wistar rats (250-300 g) were divided into two groups of 30 animals each and treated as follows: (1) control (saline, intraperitoneally) and (2) carboplatin (256 mg kg(-1), intraperitoneally). The animals (n = 6) from each group were sacrificed 1-5 days after treatment. The blood and kidneys were isolated and analyzed. Plasma creatinine, blood urea nitrogen (BUN), and blood urea levels were increased significantly in response to carboplatin in a time-dependent manner, indicating potential nephrotoxicity. Carboplatin time-dependently increased the renal platinum concentration, renal xanthine oxidase activity, increased membrane lipid peroxidation (MDA) concentration, while ratio of reduced-to-oxidized glutathione (GSH/GSSG) depleted significantly, indicating oxidative renal injury. Renal anti-oxidant enzymes, such as cytosolic copper/zinc-superoxide dismutase (CuZn-SOD) and mitochondrial manganese (Mn)-SOD, catalase (CAT), and glutathione peroxidase (GSH-Px) activities were decreased significantly due to carboplatin 3-5 days post-treatment. The protein expressions of renal CuZn-SOD and Mn-SOD significantly depleted 3-5 days after carboplatin administration, indicating decline in de novo synthesis of enzyme proteins. The data suggested that carboplatin caused time-dependent oxidative renal injury, as evidenced by renal anti-oxidant depletion, enhanced lipid peroxidation, platinum content, plasma creatinine BUN, and blood urea levels in rats.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15225673     DOI: 10.1016/j.phrs.2004.04.001

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  10 in total

1.  Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs.

Authors:  Dimitra T Stefanou; Hara Episkopou; Soterios A Kyrtopoulos; Aristotelis Bamias; Maria Gkotzamanidou; Christina Bamia; Christina Liakou; Margarita Bekyrou; Petros P Sfikakis; Meletios-Athanasios Dimopoulos; Vassilis L Souliotis
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

2.  Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors.

Authors:  Weilian Yang; Tianyao Huo; Rolf F Barth; Nilendu Gupta; Michael Weldon; John C Grecula; Brian D Ross; Benjamin A Hoff; Ting-Chao Chou; Julia Rousseau; Hélène Elleaume
Journal:  J Neurooncol       Date:  2010-06-25       Impact factor: 4.130

3.  Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth.

Authors:  Bikul Das; Roula Antoon; Rika Tsuchida; Shamim Lotfi; Olena Morozova; Walid Farhat; David Malkin; Gideon Koren; Herman Yeger; Sylvain Baruchel
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

4.  Protective effects of leflunomide on intestinal ischemia-reperfusion injury: leflunomide against intestinal ischemia-reperfusion.

Authors:  Yuksel Yildiz; Hayrullah Kose; Serpil Cecen; Kemal Ergin; Ece Mine Demir; Mukadder Serter
Journal:  Dig Dis Sci       Date:  2009-02-20       Impact factor: 3.199

5.  Successful delivery of chemotherapy to treat small-cell prostate cancer in a patient undergoing haemodialysis.

Authors:  Andrew McPartlin; Claudia Grimaldo; Jeanette Lyons; Daniel Burke; Sandip Mitra; Ananya Choudhury
Journal:  Clin Kidney J       Date:  2014-09-16

6.  Oxidative stress-mediated intrinsic apoptosis in human promyelocytic leukemia HL-60 cells induced by organic arsenicals.

Authors:  Xiao-Yang Fan; Xin-You Chen; Yu-Jiao Liu; Hui-Min Zhong; Feng-Lei Jiang; Yi Liu
Journal:  Sci Rep       Date:  2016-07-19       Impact factor: 4.379

7.  Point-source burst of coordination polymer nanoparticles for tri-modality cancer therapy.

Authors:  Xiang Ling; Wenbo Han; Xiaomin Jiang; Xing Chen; Megan Rodriguez; Pingping Zhu; Tong Wu; Wenbin Lin
Journal:  Biomaterials       Date:  2021-01-29       Impact factor: 12.479

8.  Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing rats.

Authors:  Tianyao Huo; Rolf F Barth; Weilian Yang; Robin J Nakkula; Rumiana Koynova; Boris Tenchov; Abhik Ray Chaudhury; Lawrence Agius; Teni Boulikas; Helene Elleaume; Robert J Lee
Journal:  PLoS One       Date:  2012-11-13       Impact factor: 3.240

9.  Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism.

Authors:  Alois Kozubík; Alena Vaculová; Karel Soucek; Jan Vondrácek; Jaroslav Turánek; Jirina Hofmanová
Journal:  Met Based Drugs       Date:  2008

Review 10.  [Mechanism of Platinum Derivatives Induced Kidney Injury].

Authors:  Feifei Yan; Jianchun Duan; Jie Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-09-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.